Skip to search formSkip to main contentSkip to account menu

mavrilimumab

Known as: Immunoglobulin G4, Anti-(Human Granulocyte-Macrophage Colony-Stimulating-Factor Receptor alpha-Chain) (Human Monoclonal CAM-3001 Heavy Chain), Disulfide with Human Monoclonal CAM-3001 lambda-Chain, Dimer 
A human IgG4 monoclonal antibody targeting the alpha chain of the granulocyte-macrophage colony-stimulating factor receptor (GM-CSF-Ra), with… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Monoclonal Antibodies
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia
I read with great interest the paper by Della Torre et al on the effects of sarilumab in severe acute respiratory syndrome… 
Review
2017
Review
2017
Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date
The introduction of biological therapies into clinical practice has dramatically modified the natural history of chronic… 
2016
2016
Pulmonary pharmacodynamics of an anti-GM-CSFRα antibody enables therapeutic dosing that limits exposure in the lung
ABSTRACT Pulmonary alveolar proteinosis is associated with impaired alveolar macrophage differentiation due to genetic defects in… 
2016
2016
SAT0146 Earth Explorer 2, A Phase IIB Exploratory Study Evaluating Efficacy and Safety of Mavrilimumab, A Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-Alpha Monoclonal…
Background Mavrilimumab, a fully human monoclonal antibody targeting the granulocyte-macrophage colony-stimulating factor… 
2015
2015
OP0034 Efficacy and Safety of Mavrilimumab, A Fully Human Gm–CSFR-Alpha Monoclonal Antibody in Patients with Rheumatoid Arthritis: Primary Results from the Earth Explorer 1 Study
Background Of patients with RA, ∼40% of do not achieve a minimal acceptable improvement (ACR20) despite modern biologic therapy.1… 
2015
2015
FRI0167 Patient-Reported Outcomes (PROS) During Treatment with Mavrilimumab, A Fully Human Monoclonal Antibody Targeting GM–CSFR-Alpha, In the Phase IIB Earth Explorer 1 Study
Background Active RA significantly impairs patients' health-related quality of life (HRQOL) and physical function. Granulocyte… 
2015
2015
AB0445 Exposure–Efficacy Analysis of Mavrilimumab in Rheumatoid Arthritis: Modeling and Simulation of Phase II Clinical Data
Background Mavrilimumab, a fully human monoclonal antibody targeting the granulocyte-macrophage colony-stimulating factor… 
2015
2015
SAT0212 Sustained Response to Mavrilimumab in Rheumatoid Arthritis Patients VIA Suppression of Macrophage and T Cells
Background Mavrilimumab is a fully human monoclonal antibody targeting granulocyte-macrophage colony-stimulating factor receptor… 
2013
2013
Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples
Rheumatoid arthritis (RA) control and outcome has greatly improved with the efficacy of biologic disease-modifying antirheumatic… 
Review
2012
Review
2012
Mavrilimumab, a human monoclonal GM-CSF receptor-α antibody for the management of rheumatoid arthritis: a novel approach to therapy
Introduction: Mavrilimumab, formerly known as CAM-3001, a GM-CSF receptor-α antibody, is the first human monoclonal antibody to… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)